AMY (CG)

A lipidated, disulfide-cyclized 37-residue synthetic peptide studied in receptor-binding and cryo-EM structural research.

Molecular Profile

Type
Synthetic peptide (acylated, disulfide-cyclized, 37 residues)
Molecular formula
C194H312N54O59S2
Molecular weight
~4,409 g/mol
CAS number
1415456-99-3
Amino acids
37
Fatty acid chain
C20 diacid
Modification
Disulfide bridge (Cys2–Cys7); N-terminal C20 fatty-diacid acylation; proline substitutions that reduce fibrillation propensity; E14–R17 intramolecular salt bridge; C-terminal amide.

Mechanism & Target Class

A lipidated, disulfide-cyclized synthetic peptide. The N-terminal C20 fatty-diacid acylation confers reversible albumin binding. Cryo-EM structural studies have characterized an E14–R17 intramolecular salt bridge that stabilizes the central helix, proline substitutions that reduce fibrillation propensity, and a transmembrane-bundle binding mode at class B G protein–coupled receptors involving a midregion 'bypass' structural motif.

Storage & Handling

Lyophilized
-20°C (-80°C long term); powder typically stable ~24 months.
Handling
High fibrillation propensity — avoid neutral pH on storage, avoid freeze-thaw, protect from light.

Primary Database

RCSB PDB: 7BG0 ↗

References (21)

  1. Reviews

    1

    Dutta D, et al. (2024). Indian J Endocrinol Metab

    DOI: 10.4103/ijem.ijem_45_24PubMed 39676787

  2. 2

    D'Ascanio AM, et al. (2024). Cardiol Rev

    DOI: 10.1097/CRD.0000000000000513PubMed 36883831

  3. 3

    Mathiesen DS, et al. (2021). Front Endocrinol

    DOI: 10.3389/fendo.2020.617400PubMed 33488526

  4. 4

    Walker CS, et al. (2025). Nat Rev Endocrinol

    DOI: 10.1038/s41574-025-01125-9PubMed 40360789

  5. 5

    Lutz TA, et al. (2026). Br J Pharmacol

    DOI: 10.1111/bph.70484PubMed 42068083

  6. 6

    Mathiesen DS, et al. (2022). Curr Opin Endocrinol Diabetes Obes

    DOI: 10.1097/MED.0000000000000716PubMed 35066542

  7. Clinical

    7

    Davies MJ, et al. (2025). N Engl J Med

    DOI: 10.1056/NEJMoa2502082PubMed 40544432

  8. 8

    Garvey WT, et al. (2025). N Engl J Med

    DOI: 10.1056/NEJMoa2502081PubMed 40544433

  9. 9

    Gabe MBN, et al. (2024). Diabetes Obes Metab

    DOI: 10.1111/dom.15951PubMed 39279639

  10. 10

    Frias JP, et al. (2023). Lancet

    DOI: 10.1016/S0140-6736(23)01163-7PubMed 37364590

  11. 11

    Enebo LB, et al. (2021). Lancet

    DOI: 10.1016/S0140-6736(21)00845-XPubMed 33894838

  12. 12

    Becerril S, Frühbeck G. (2021). Lancet

    DOI: 10.1016/S0140-6736(21)00944-2PubMed 33894837

  13. 13

    Lau DCW, et al. (2021). Lancet

    DOI: 10.1016/S0140-6736(21)01751-7PubMed 34798060

  14. Primary research

    14

    Cao J, et al. (2025). Nat Commun

    DOI: 10.1038/s41467-025-58680-yPubMed 40204768

  15. 15

    Gu YM, Yuan QN, Li X, et al. (2025). Acta Pharmacol Sin

    DOI: 10.1038/s41401-025-01635-2

  16. 16

    Cao J, et al. (2023). Nat Chem Biol

    DOI: 10.1038/s41589-023-01393-4

  17. 17

    Cao J, et al. (2022). Science

    DOI: 10.1126/science.abm9609PubMed 35324283

  18. 18

    Larsen AT, et al. (2022). Biomed Pharmacother

    PubMed 36242844

  19. 19

    Carvas AO, Folgueira C, et al. (2025). eBioMedicine

    PubMed 40609154

  20. 20

    Fletcher MM, et al. (2021). J Pharmacol Exp Ther

    DOI: 10.1124/jpet.121.000567PubMed 33727283

  21. 21

    Kruse T, et al. (2021). J Med Chem

    DOI: 10.1021/acs.jmedchem.1c00565PubMed 34288673